Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China

Compared to chemotherapy, promising results have been obtained by blocking the PD-1 pathway using antibodies that inhibit programmed cell death protein 1 (PD-1) or programmed cell death protein ligand 1 (PD-L1). Furthermore, global researchers and doctors are exploring how to optimize this immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Si-Yang, Wu, Yi-Long
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499002/
https://www.ncbi.nlm.nih.gov/pubmed/28679395
http://dx.doi.org/10.1186/s13045-017-0506-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5499002/
https://www.ncbi.nlm.nih.gov/pubmed/28679395
http://dx.doi.org/10.1186/s13045-017-0506-z

Ejemplares similares